These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16032519)

  • 1. Systemic low-grade inflammation and risk of coronary heart disease: results from the MONICA/KORA Augsburg cohort studies.
    Koenig W; Meisinger C; Baumert J; Khuseyinova N; Löwel H
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S62-7. PubMed ID: 16032519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Psychosocial factors as risk for coronary heart disease--status with special reference to the KORA platform].
    Ladwig KH; Marten-Mittag B; Baumert J;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S86-93. PubMed ID: 16032523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and type 2 diabetes: results from KORA Augsburg.
    Herder C; Illig T; Rathmann W; Martin S; Haastert B; Müller-Scholze S; Holle R; Thorand B; Koenig W; Wichmann HE; Kolb H;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S115-21. PubMed ID: 16032528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.
    Koenig W; Löwel H; Baumert J; Meisinger C
    Circulation; 2004 Mar; 109(11):1349-53. PubMed ID: 15023871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Case-cohort studies: an effective design for the investigation of biomarkers as risk factors for chronic diseases--demonstrated by the example of the MONICA/KORA Augsburg Case-Cohort Study 1984-2002].
    Thorand B; Schneider A; Baumert J; Döring A; Marowsky-Köppl M; Heier M; Meisinger C; Löwel H
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S98-102. PubMed ID: 16032525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes mellitus in Augsburg--an epidemiological overview.
    Meisinger C; Döring A; Heier M; Thorand B; Löwel H;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S103-9. PubMed ID: 16032526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ankle-brachial index and peripheral arterial disease.
    Lamina C; Meisinger C; Heid IM; Rantner B; Döring A; Löwel H; Wichmann HE; Kronenberg F
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S57-61. PubMed ID: 16032518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Worldwide WHO MONICA Project: results and perspectives].
    Keil U
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S38-45. PubMed ID: 16032516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.
    Koenig W; Khuseyinova N; Baumert J; Thorand B; Loewel H; Chambless L; Meisinger C; Schneider A; Martin S; Kolb H; Herder C
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2745-51. PubMed ID: 17008587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetics of type 2 diabetes: impact of interleukin-6 gene variants.
    Illig T; Bongardt F; Schöpfer-Wendels A; Huth C; Heid I; Rathmann W; Martin S; Vollmert C; Holle R; Thorand B; Wichmann HE; Koenig W; Kolb H; Herder C;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S122-6. PubMed ID: 16032529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The population-based acute myocardial infarction (AMI) registry of the MONICA/KORA study region of Augsburg.
    Löwel H; Meisinger C; Heier M; Hörmann A
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S31-7. PubMed ID: 16032515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dysfunction of the hypothalamus-pituitary-adrenal system--background variable of relevant cardiovascular risk factors?--description of a cooperative project].
    Lederbogen F; Deuschle Für Die Kora-Studiengruppe M
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S94-7. PubMed ID: 16032524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MONICA Augsburg surveys--basis for prospective cohort studies.
    Löwel H; Döring A; Schneider A; Heier M; Thorand B; Meisinger C;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S13-8. PubMed ID: 16032512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
    Oldgren J; James SK; Siegbahn A; Wallentin L
    Eur Heart J; 2007 Mar; 28(6):699-704. PubMed ID: 17314110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Particles in the outside air increase the risk of cardiovascular diseases].
    Peters A;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S79-85. PubMed ID: 16032522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.
    Thorand B; Baumert J; Kolb H; Meisinger C; Chambless L; Koenig W; Herder C
    Diabetes Care; 2007 Apr; 30(4):854-60. PubMed ID: 17392546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
    Corson MA; Jones PH; Davidson MH
    Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.